| Ano | Produção | Detalhes |
|---|
| 2018 | BERTOLAMI, ADRIANA ; DE LIMA-JÚNIOR, JOSÉ CARLOS ; CINTRA, RIOBALDO MARCELO ; Carvalho, Luiz Sérgio ; DE C GONZAGA, CAROLINA ; SULZBACH, MARTHA L ; PETISCO, ANA CLÁUDIA G P ; BARBOSA, JOSÉ EDUARDO M ; FALUDI, ANDRÉ A ; PLUTZKY, JORGE ; BERTOLAMI, MARCELO C ; SPOSITO, ANDREI C. Adiponectin concentration data improve the estimation of atherosclerotic risk in normo and in overweight subjects. CLINICAL ENDOCRINOLOGY, v. 88, p. 388-396, 2018. | |
| 2018 | CARVALHO, LUIZ SÉRGIO F. DE ; SILVA, THIAGO QUINAGLIA AC ; COELHO-FILHO, OTÁVIO RIZZI. Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality. Arquivos Brasileiros de Cardiologia, v. 111, p. 808-809, 2018. | |
| 2018 | DE CARVALHO, LUIZ SÉRGIO F. ; CAMPOS, ALESSANDRA M. ; Sposito, Andrei C.. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. DIABETES CARE, v. 41, p. 364-367, 2018. | |
| 2018 | DE CARVALHO, LUIZ SÉRGIO F. ; CAMPOS, ALESSANDRA M. ; Sposito, Andrei C.. Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367. DIABETES CARE, v. 41, p. e70-e71, 2018. | |
| 2018 | DE CARVALHO, LUIZ SÉRGIO F.. Total cholesterol and the risk of stroke: A double-edged sword or a blunt knife?. ATHEROSCLEROSIS, v. 270, p. 191-192, 2018. | |
| 2018 | SOARES, ALEXANDRE A.S. ; Carvalho, Luiz Sergio F. ; BONILHA, ISABELLA ; VIRGINIO, VITOR W. ; JUNIOR, WILSON NADRUZ ; COELHO-FILHO, OTAVIO RIZZI ; Quinaglia e Silva, Jose C. ; JUNIOR, ORLANDO PETRUCCI ; Sposito, Andrei C.. Adverse interaction between HDL and the mass of myocardial infarction. ATHEROSCLEROSIS, v. 281, p. 9-16, 2018. | |
| 2018 | Sposito, Andrei C. ; BERWANGER, OTÁVIO ; DE CARVALHO, LUIZ SÉRGIO F. ; SARAIVA, JOSÉ FRANCISCO KERR. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovascular Diabetology, v. 17, p. 1-19, 2018. | |
